Literature DB >> 11232009

The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33.

J F Rehfeld1, G Sun, T Christensen, J G Hillingsø.   

Abstract

Cholecystokinin (CCK) occurs in multiple molecular forms; the major ones are CCK-58, -33, -22, and -8. Their relative abundance in human plasma and intestine, however, is debated. To settle the issue, extracts of intestinal biopsies and plasma from 10 human subjects have been examined by chromatography, enzyme cleavages, and measurements using a library of sequence-specific RIAs. Plasma samples were drawn in the fasting state and at intervals after a meal. The abundance of the larger forms varied with the 8 C-terminal assays in the library, as 2 assays overestimated and 3 underestimated the amounts present. One assay, however, measured carboxyamidated and O:-sulfated CCKs with equimolar potency before and after tryptic cleavage. This assay showed that the predominant plasma form is CCK-33, both in the fasting state ( approximately 51%) and postprandially ( approximately 57%), whereas CCK-22 is the second most abundant ( approximately 34% and 30%, respectively). In contrast, CCK-58 is less abundant in human intestines ( approximately 18%) and plasma ( approximately 11%). Its predominance in feline intestines, however, was confirmed. Hence, the results show a significant species variation and emphasize the necessity of highly specific and well characterized assays in molecular studies of CCK.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11232009     DOI: 10.1210/jcem.86.1.7148

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

Review 1.  Effects of bioactive agents on biliary motor function.

Authors:  Charmaine M Woods; Gary M Mawe; Eldon A Shaffer; James Toouli; Gino T P Saccone
Journal:  Curr Gastroenterol Rep       Date:  2003-04

Review 2.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 4.  Gastrointestinal hormones regulating appetite.

Authors:  Owais Chaudhri; Caroline Small; Steve Bloom
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 5.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 6.  The endoproteolytic maturation of progastrin and procholecystokinin.

Authors:  Jens F Rehfeld
Journal:  J Mol Med (Berl)       Date:  2006-05-06       Impact factor: 4.599

Review 7.  Anxiety, Depression, and the Microbiome: A Role for Gut Peptides.

Authors:  Gilliard Lach; Harriet Schellekens; Timothy G Dinan; John F Cryan
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

8.  Cardiomyocyte expression and cell-specific processing of procholecystokinin.

Authors:  Jens P Goetze; Anders H Johnsen; Caroline Kistorp; Finn Gustafsson; Camilla B Johnbeck; Jens F Rehfeld
Journal:  J Biol Chem       Date:  2015-01-27       Impact factor: 5.157

9.  Interactions of gastrointestinal peptides: ghrelin and its anorexigenic antagonists.

Authors:  Anna-Sophia Wisser; Piet Habbel; Bertram Wiedenmann; Burghard F Klapp; Hubert Mönnikes; Peter Kobelt
Journal:  Int J Pept       Date:  2010-01-06

Review 10.  Overview of exocrine pancreatic pathobiology.

Authors:  Arun R Pandiri
Journal:  Toxicol Pathol       Date:  2013-11-03       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.